News & Events about Dyne Therapeutics Inc.
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief ...
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating)s share price gapped up before the market opened on Wednesday following insider buying activity. The stock had previously closed at $12.20, but opened at $12.65. Dyne Therapeutics shares last traded at $14.15, with a volume of 2,801 ...
Globe Newswire
5 months ago
- Appointment Expands Dynes Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics ...